General Patent Corporation Secures 15th Licensee for "Contactless Cards" Patent Portfolio
CARDPro China Takes a License from Leighton Technologies
Ryogen Is Awarded Patent for Polynucleotides Related to Tumor-Suppressing Subtransferable Candidate 4
This Patent Brings Ryogen's Gene-Related Portfolio to 30 Issued U.S. Patents
Suffern, N.Y., June 24, 2014 − Ryogen LLC, a genomics R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded a new patent, bringing the total number of U.S. Patents issued to Ryogen to 30.
U.S. Patent No. 8,722,865, titled "Isolated genomic polynucleotide fragments from p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4)," is the first Ryogen patent to be issued after the seminal Myriad decision of the U.S. Supreme Court that clarified the patentability of genomic constructs.
Lessons from Alice in Patent-Land
Yesterday, the Supreme Court issued its decision in Alice Corporation Pty. Ltd. V. CLS Bank International et. al.. What are the takeaways of this decision?
Here, in a summary form, are five lessons we can learn from Alice:
- Financial methods, even if computerized, are not patentable when well-known methods are merely implemented on a generic computer.
Meet the Biggest Patent Troll of All: Microsoft
This is not the first instance of a major, high-tech corporation asserting patents for inventions it did not invent and does not practice. This is simply the most recent instance of a major, high-tech corporation asserting patents for inventions it did not invent and does not practice.
Tesla Tosses its Patents: Do-Good or Do-Well Strategy?
If you want to join the Open Source movement, hop aboard an electric car for a ride. Or so says Tesla. Yesterday they opened their patents to all. Their press release begins with a dramatic statement, “Yesterday, there was a wall of Tesla patents in the lobby of our Palo Alto headquarters. That is no longer the case. They have been removed, in the spirit of the open source movement.”